Annovis Bio to post late-stage data for Parkinson's drug in June
Seeking Alpha News (Thu, 9-May 3:34 PM ET)
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease
Globe Newswire (Thu, 9-May 7:30 AM ET)
Annovis Bio Issues Key Update on Corporate Progress
TipRanks (Mon, 6-May 5:22 PM ET)
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Globe Newswire (Mon, 6-May 7:30 AM ET)
Globe Newswire (Mon, 29-Apr 10:10 AM ET)
Globe Newswire (Tue, 2-Apr 7:30 AM ET)
Globe Newswire (Mon, 1-Apr 8:00 AM ET)
Globe Newswire (Wed, 20-Mar 7:30 AM ET)
Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Globe Newswire (Wed, 14-Feb 7:30 AM ET)
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Annovis Bio trades on the NYSE stock market under the symbol ANVS.
As of May 9, 2024, ANVS stock price climbed to $6.03 with 2,076,028 million shares trading.
ANVS has a beta of 1.44, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.01 to the broad based SPY ETF.
ANVS has a market cap of $66.40 million. This is considered a Micro Cap stock.
In the last 3 years, ANVS stock traded as high as $132.00 and as low as $4.79.
The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC.
ANVS has underperformed the market in the last year with a price return of -59.3% while the SPY ETF gained +27.7%. ANVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.4% and -52.7%, respectively, while the SPY returned +4.7% and +2.9%, respectively.
ANVS support price is $4.38 and resistance is $5.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS stock will trade within this expected range on the day.